Welcome to our dedicated page for Psyence Biomedical Ltd. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence BioMed has begun dosing patients in a Phase IIb clinical trial of NPX-5, a 25mg nature-derived psilocybin candidate, for Adjustment Disorder in cancer patients in a palliative care setting across clinical sites in Australia.
The randomized, double-blind, three-arm study is designed to evaluate both the safety and therapeutic potential of NPX-5 within a structured, therapy-supported treatment model. This is the first active clinical evaluation of NPX-5 and marks a shift toward systematic human data generation within the company’s Australian clinical network.
The program is positioned as a core element of Psyence BioMed’s vertically integrated platform, which combines GMP-compliant manufacturing, clinical development, and global supply capabilities, with the aim of addressing significant unmet mental health needs using nature-derived psychedelic-based therapeutics.
Psyence Biomedical Ltd. updated its common stock purchase agreement with White Lion Capital to add a new intraday share sale option. During the commitment period, Psyence can issue an Intraday Purchase Notice requiring White Lion to buy common shares up to 5% of the Average Daily Trading Volume per notice.
The purchase price is the lowest traded price during a one-hour valuation window after White Lion’s written acceptance, subject to a floor price set in each notice. White Lion must consent within 15 minutes and settle within two business days. In connection with the amendment, White Lion will pay Psyence a $22,000 legal document preparation fee.
Psyence Biomedical Ltd. filed a Form 6-K highlighting a press release that welcomes anticipated U.S. executive action to further evaluate the safety and therapeutic potential of ibogaine. The company notes that ibogaine is being studied for difficult conditions such as PTSD, addiction, and other serious neurological and mental health disorders.
Psyence BioMed emphasizes its strategic investment in PsyLabs, describing a leading position in GMP-compliant ibogaine manufacturing and an ethically sourced ibogaine supply chain within the compound’s native African ecosystem. The company presents its vertically integrated platform—ethical sourcing, GMP manufacturing, and clinical development—as support for future regulated ibogaine research, while cautioning that any U.S. executive order is not assured and may not affect its operations.
Psyence BioMed Ltd. is expanding its Australian clinical site network from three to five locations to support its ongoing Phase IIb trial of natural psilocybin (NPX-5) for Adjustment Disorder in cancer patients in palliative care. New partners Ramsay Health Care and NeuroCentrix join existing sites in Perth and Melbourne. Psyence BioMed is supplying fully GMP-compliant NPX-5 capsules (1mg and 5mg) through PsyLabs’ GMP-controlled facility, supporting patient dosing and advancing NPX-5 as its lead clinical drug candidate.
Psyence Biomedical Ltd. describes several corporate developments. The company’s subsidiary agreed to lend US$251,110 to Curiosum Ltd. at Royal Bank prime plus 1%, maturing three months after the February 9, 2026 loan agreement, to fund Curiosum’s purchase of 50,220 Psyence Biomedical shares from the KAOS Group under a prior settlement.
The company also completed a share-for-share exchange tied to Psyence Labs Ltd.’s exercised put option. Psyence Labs issued 2,900 of its shares valued at US$5,000,000, and Psyence Biomedical issued 1,146,159 common shares based on a 30‑day VWAP, with no cash changing hands. Following this issuance, Psyence Labs beneficially owns about 49.98% of Psyence Biomedical’s common shares, compared with 1,147,148 shares outstanding before the transaction.
On the governance side, director Seth Feuerstein resigned, stating no disagreement with the company. The board appointed Sashank Pillay as an independent director and committee member, citing his experience in cultivation, production and regulated substance operations.
Psyence Biomedical Ltd. plans a share-for-share transaction with affiliate Psyence Labs Ltd. (PsyLabs) after PsyLabs exercised a put option for a US$5,000,000 equity investment. PsyLabs will issue 2,900 PsyLabs shares to Psyence Biomedical, valued at US$5,000,000 based on a US$1,724 per-share valuation.
In return, Psyence Biomedical will issue 1,146,159 common shares to PsyLabs, calculated using a 30‑day VWAP of US$4,36 per share, with no cash changing hands. After closing, PsyLabs is expected to beneficially own about 49.98% of Psyence Biomedical’s outstanding common shares, implying substantial dilution to existing holders. Because executives have interests in PsyLabs, an independent special committee reviewed the deal and determined it to be fair and in the best interests of non‑conflicted shareholders.
Psyence Biomedical Ltd. Schedule 13G reports that Weiner Jeffrey David beneficially owns 51,850 common shares, representing 5.07% of the class as of 02/13/2026.
The filing shows Mr. Weiner has sole voting and dispositive power over all 51,850 shares. The filing gives the issuer address as 121 Richmond Street West, Penthouse, Suite 1300, Toronto, Ontario, Canada.
Psyence Biomedical Ltd. held its adjourned annual and special shareholder meeting, where all proposals were approved, restoring normal corporate governance. Shareholders elected all director nominees and confirmed MNP LLP as auditor with more than 95% of votes cast in favour.
Investors also granted the board authority to implement one or more consolidations of the issued and outstanding common shares at a ratio of up to 250:1, to be used at the board’s discretion and subject to regulatory and exchange approvals. Forward-looking statements emphasize uncertainties around maintaining Nasdaq listing compliance, potential share price volatility, and development and clinical trial risks.
Psyence Biomedical Ltd. reported that its board of directors ratified a put option agreement with PsyLabs, a developer and manufacturer of pharmaceutical-grade psychedelic compounds. The agreement gives PsyLabs the right, but not the obligation, to require Psyence BioMed to make an additional equity investment in PsyLabs through a share-for-share exchange at arm’s-length fair market value, subject to stated conditions.
The put option is part of a broader strategic and commercial relationship that includes licensing arrangements giving Psyence BioMed access to PsyLabs’ investigational and commercial-scale manufacturing capabilities for psychedelic active ingredients. The structure is intended to secure predictable, reliable supply and long-term alignment while preserving Psyence BioMed’s near-term financial flexibility.
Certain Psyence BioMed executives provide consulting services to PsyLabs and collectively own less than 13% of PsyLabs’ outstanding shares. To address these relationships, the board formed a special committee of independent and disinterested directors, which reviewed the transaction, its commercial rationale, and an independent third-party valuation of PsyLabs before ratifying the agreement.
Psyence Biomedical Ltd. has settled a shareholder dispute with KAOS Capital Ltd. and Adam Arviv. The company will pay KAOS an aggregate US $1,500,000 and release KAOS from a prior CDN $75,000 cost award ordered by the Ontario Superior Court.
As part of the settlement, KAOS will sell all its 50,220 common shares of Psyence to a third party designated by the company at US $5 per share. The deal includes a full retraction of KAOS’s unproven allegations, mutual releases of claims, and no admission of liability or wrongdoing by Psyence, its board, or officers. The settlement will be funded from cash on hand.